A botulinum toxin-derived targeted secretion inhibitor downregulates the GH/IGF1 axis
Publié dansThe Journal of clinical investigation, vol. 122, no. 9, p. 3295-3306
Date de publication2012
Résumé
Mots-clés
- Acromegaly/drug therapy
- Animals
- Area Under Curve
- Body Weight/drug effects
- Botulinum Toxins/chemistry/genetics
- Cell Line
- Cyclic AMP/metabolism
- Dose-Response Relationship, Drug
- Down-Regulation/drug effects
- Growth Hormone/blood/secretion
- Growth Hormone-Releasing Hormone/chemistry/genetics
- Growth Inhibitors/chemistry/pharmacology
- Growth Plate/drug effects/growth & development/pathology
- Insulin-Like Growth Factor I/genetics/metabolism/secretion
- Liver/metabolism
- Male
- Organ Size/drug effects
- Pituitary Gland/drug effects/metabolism/pathology
- Prolactin/metabolism
- Protein Structure, Tertiary
- Proteolysis
- Rats
- Rats, Sprague-Dawley
- Recombinant Fusion Proteins/chemistry/pharmacology
- Vesicle-Associated Membrane Protein 2/chemistry
Structure d'affiliation
Groupe de recherche
Citation (format ISO)
SOMM, Emmanuel et al. A botulinum toxin-derived targeted secretion inhibitor downregulates the GH/IGF1 axis. In: The Journal of clinical investigation, 2012, vol. 122, n° 9, p. 3295–3306. doi: 10.1172/JCI63232
Fichiers principaux (1)
Article (Published version)
Identifiants
- PID : unige:28593
- DOI : 10.1172/JCI63232
- PMID : 22850878
ISSN du journal0021-9738